Publications by authors named "Quentin Lecocq"

Claim this Profile
S
Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
Heleen Hanssens, Fien Meeus, Yannick De Vlaeminck, Quentin Lecocq, Janik Puttemans

Front Immunol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of [Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I).
Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Quentin Lecocq

J Nucl Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted α-Therapy Using Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment.
Thomas Ertveldt, Ahmet Krasniqi, Hannelore Ceuppens, Janik Puttemans, Yana Dekempeneer, Quentin Lecocq

J Nucl Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Thomas Ertveldt, Lien De Beck, Kirsten De Ridder, Hanne Locy, Wout de Mey, Quentin Lecocq

Mol Cancer Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging applications of nanobodies in cancer therapy.
Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq

Int Rev Cell Mol Biol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma.
Lien De Beck, Robin Maximilian Awad, Veronica Basso, Noelia Casares, Kirsten De Ridder, Quentin Lecocq

Front Immunol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy.
Kirsten De Ridder, Hanne Locy, Elisa Piccioni, Miren Ibarra Zuazo, Robin Maximilian Awad, Quentin Lecocq

Front Immunol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade.
Quentin Lecocq, Robin Maximilian Awad, Yannick De Vlaeminck, Wout de Mey, Thomas Ertveldt

J Nucl Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade.
Robin Maximilian Awad, Quentin Lecocq, Katty Zeven, Thomas Ertveldt, Lien De Beck

Mol Ther Methods Clin Dev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry.
Dora Mugoli Chigoho, Quentin Lecocq, Robin Maximilian Awad, Karine Breckpot, Nick Devoogdt

Pharmaceuticals (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.
Quentin Lecocq, Marleen Keyaerts, Nick Devoogdt, Karine Breckpot

Int J Mol Sci· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development.
Yannick De De Vlaeminck, Stefano Bonelli, Robin Maximilian Awad, Maarten Dewilde, Sabrina Rizzolio, Quentin Lecocq

Cancers (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theranostics in immuno-oncology using nanobody derivatives.
Quentin Lecocq, Yannick De Vlaeminck, Heleen Hanssens, Matthias D'Huyvetter, Geert Raes

Theranostics· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Efficacy of Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer.
Yana Dekempeneer, Vicky Caveliers, Maarten Ooms, Dominic Maertens, Mireille Gysemans, Quentin Lecocq

Mol Pharm· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation.
Jessica Bridoux, Katrijn Broos, Quentin Lecocq, Pieterjan Debie, Charlotte Martin

Biomolecules· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Targeted α- and β-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.
Janik Puttemans, Yana Dekempeneer, Jos L Eersels, Heleen Hanssens, Pieterjan Debie, Quentin Lecocq

Cancers (Basel)· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use.
Quentin Lecocq, Katty Zeven, Yannick De Vlaeminck, Sandrina Martens, Sam Massa

Biomolecules· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy.
Katrijn Broos, Quentin Lecocq, Geert Raes, Nick Devoogdt, Marleen Keyaerts

Theranostics· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production.
Katrijn Broos, Quentin Lecocq, Brenda De Keersmaecker, Geert Raes, Jurgen Corthals

Vaccines (Basel)· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.
Katrijn Broos, Quentin Lecocq, Catarina Xavier, Jessica Bridoux, Tham T Nguyen

Cancers (Basel)· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages.
Yannick De Vlaeminck, Quentin Lecocq, Philippe Giron, Carlo Heirman, Xenia Geeraerts

J Control Release· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.
Maarten Versteven, Johan M J Van den Bergh, Katrijn Broos, Fumihiro Fujiki, Diana Campillo-Davo, Quentin Lecocq

Oncotarget· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Katrijn Broos, Marleen Keyaerts, Quentin Lecocq, Dries Renmans, Tham Nguyen

Oncotarget· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis